PT-141 vs Melanotan II: Sexual Desire vs Tanning (and the Safety Gap)

PT-141 and Melanotan II are close chemical cousins — PT-141 was literally developed from Melanotan II — but they sit on opposite sides of the safety and regulatory line. One is an FDA-approved drug for sexual desire; the other is an unapproved tanning compound with documented serious toxicity. This guide compares receptor selectivity, primary effects, evidence, and safety. For the single-compound deep dives, see What Is PT-141? and What Is Melanotan II?.

The Short Answer

PT-141 (bremelanotide) is a more MC4R-selective melanocortin agonist, FDA-approved for sexual desire (Vyleesi, 2019), with Phase 3 trial data; Melanotan II is a broad, non-selective melanocortin agonist used for tanning, unapproved anywhere, with a narrow safety window and documented rhabdomyolysis and renal infarction. PT-141 was engineered from Melanotan II specifically to keep the sexual-function (MC4R) effect while dialing down the tanning (MC1R) activity. For research, PT-141's characterized safety profile makes it the more tractable compound. (Bremelanotide approval, MT-II rhabdomyolysis)

Same Origin, Different Targets

Both are cyclic heptapeptides of nearly identical molecular weight (~1,025 vs ~1,024 Da). The difference is receptor selectivity:

• PT-141 (Bremelanotide) acts across melanocortin receptors but with highest functional relevance at MC4R in the hypothalamus, where it triggers dopamine release tied to sexual desire — with comparatively little MC1R (pigment) activity. (Bremelanotide approval)
• Melanotan II (MT-II) is a non-selective agonist at MC1R, MC3R, MC4R, and MC5R. MC1R drives the tanning (melanogenesis); MC4R drives the sexual and appetite effects; the broad activation is also why it has a wider side-effect burden. (MT-II melanogenesis)

In short: PT-141 narrowed the target to keep the benefit and cut the tanning; MT-II hits everything.

Side-by-Side Snapshot

Effects & Evidence

PT-141 — desire, centrally. It acts in the hypothalamus to increase sexual desire itself, independent of the blood-flow (PDE5) pathway that Viagra/Cialis use. Two Phase 3 RECONNECT trials in premenopausal women with hypoactive sexual desire disorder (HSDD) showed statistically significant improvements in satisfying sexual events and desire scores, leading to FDA approval as Vyleesi in 2019. Effect sizes were modest but the safety dataset is real and reviewed. (Bremelanotide Phase 3, Bremelanotide approval)

Melanotan II — tanning, with sexual side effects. Its primary research use is UV-independent skin pigmentation via MC1R, with visible tanning after 5–10 daily injections. Its MC4R activity also produces spontaneous erections and reduced appetite — in fact, MT-II's sexual side effects in tanning trials are what led researchers to develop PT-141 in the first place. Evidence is largely case reports and small early studies, not Phase 3 RCTs. (MT-II melanogenesis, MT-II for ED)

The Safety Gap

This is the most important part of the comparison.

• PT-141 has a characterized Phase 3 safety profile: nausea (~40%), flushing (~20%), injection-site reactions, and a transient ~6 mmHg systolic blood-pressure rise that resolves within 12 hours. Uncontrolled hypertension and cardiovascular disease are contraindications. (Bremelanotide approval)
• Melanotan II has a narrow therapeutic window and documented serious harms: a case report recorded rhabdomyolysis (CPK 17,773 IU/L) after a single 6 mg injection, plus a case of renal infarction. Its MC1R activity also drives melanocyte proliferation, with reports of darkening/irregular moles — making it contraindicated in anyone with a personal/family history of melanoma or atypical moles. (MT-II rhabdomyolysis)

For research purposes, PT-141's Phase 3 dose-response data and regulatory history make it substantially more tractable and safer to characterize than MT-II.

Which Should You Choose?

• Sexual desire research, or an approved option → PT-141 (the only FDA-approved choice; works in both sexes by mechanism).
• Tanning → MT-II is the compound that produces it, but carries serious, documented safety risks and no approval — review the Melanotan II safety profile carefully first.
• Lowest-risk melanocortin research → PT-141, because of its narrower target and characterized safety data.

Both raise blood pressure transiently and both are contraindicated in cardiovascular disease.

FAQ

Is PT-141 the same as Melanotan II?
No, but they're closely related. PT-141 (bremelanotide) was developed directly from Melanotan II by researchers studying the sexual side effects seen in MT-II tanning trials. PT-141 was engineered to be more MC4R-focused (sexual function) with less MC1R tanning activity. PT-141 completed Phase 3 trials and is FDA-approved; MT-II is not approved anywhere. (Bremelanotide approval)

What's the main difference between PT-141 and Melanotan II?
PT-141 is more selective for MC4R and is used for sexual desire; Melanotan II is non-selective (MC1R/MC3R/MC4R/MC5R) and is used primarily for tanning, with sexual and appetite effects as well. PT-141 is FDA-approved with Phase 3 data; MT-II is unapproved with a much broader and more dangerous side-effect profile.

Which is safer, PT-141 or Melanotan II?
PT-141 has a far better-characterized safety profile from Phase 3 trials, with mostly transient effects (nausea, flushing, brief blood-pressure rise). Melanotan II has documented serious toxicity, including rhabdomyolysis and renal infarction at high doses, plus mole/melanoma risk from its MC1R activity. For safety, PT-141 is the clear choice. (MT-II rhabdomyolysis)

Does Melanotan II improve sexual function like PT-141?
Yes — MT-II activates MC4R, the same receptor responsible for PT-141's sexual effects, and early studies showed spontaneous erections and increased desire. But MT-II also activates MC1R and other receptors, producing tanning and a wider side-effect burden, and it has no Phase 3 evidence or approval. PT-141 isolates the sexual-function benefit with far better safety data. (MT-II for ED)

Is either one FDA-approved?
PT-141 (bremelanotide) is FDA-approved as Vyleesi, indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Melanotan II is not approved by the FDA, EMA, or any major regulator for any use — it is a research compound only. (Bremelanotide approval)

Does PT-141 cause tanning like Melanotan II?
Only minimally. PT-141 was specifically designed to reduce MC1R (pigment) activity, so hyperpigmentation occurs in only about 1% of patients with on-demand dosing. Melanotan II, by contrast, produces prominent tanning because strong MC1R activation is its intended primary effect.

Next Steps

For reconstitution math and dosing tables, see the PT-141 10 mg Protocol and Melanotan II 10 mg Protocol, or use the PT-141 calculator and Melanotan II calculator.

Bottom line: PT-141 is the targeted, FDA-approved sexual-desire peptide; Melanotan II is the broad-acting tanning compound with a serious, documented safety gap. They share an origin but not a risk profile.